StockData
Revolution Medicines, Inc. logo

Revolution Medicines, Inc.

RVMDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMDW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$161.20+1.77 (+1.11%)

Close on Nov 20, 2026Market cap $34.55BP/E –Yield –

Revolution Medicines 2033 Convertible Senior Notes by Quarter

2033 Convertible Senior Notes — Carrying value (net of unamortized issuance costs) ($M) ($M)

Revolution Medicines 2033 Convertible Senior Notes: $488M in Q3 2026, up 180,596.3% from a year earlier.

Latest, Q3 2026
488
Period ended Sep 30, 2026
Change on a year earlier
+180,596.3%
0.27 in Q3 2025
History
5 quarters
Since Q3 2025
Sources
4
Documents cited below

Where the Q3 2026 figure comes from

Source: Form 10-Q (filed 2026-11-04) ↗

Reported in Form 10-Q / 10-K Consolidated Balance Sheets & Debt Note.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEnded2033 Convertible Senior Notes — Carrying value (net of unamortized issuance costs) ($M) ($M)Year on yearSource
Q3 2026Sep 30, 2026488+180,596.3%Form 10-Q (filed 2026-11-04) ↗
Q2 2026Jun 30, 2026487–Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 20260.24–Form 10-Q (filed 2026-05-06) ↗
Q4 2025Dec 31, 20250–Form 10-Q (filed 2026-11-04) ↗
Q3 2025Sep 30, 20250.27–Form 10-Q (filed 2025-11-05) ↗

Cite this data

StockData. (2026). Revolution Medicines 2033 Convertible Senior Notes ($M), quarterly Q3 2025–Q3 2026 [Data set]. Compiled from Revolution Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/rvmd/kpis/conv-notes-carrying

See every metric in the Revolution Medicines KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?